10.00AM-3.00PM TUESDAY, MARCH 22

10:00 am Utilizing the Superior Antibody-Dependent Cellular Cytotoxicity, Effector Functions, & Improved Persistence of g-NK Cells When Compared to Conventional NK cells

  • Austin Bigley Vice President & Director of Research & Development , Indapta Therapeutics


  • Discussing the enhanced in vivo efficacy and persistence of g-NK cells and the ability of g-NK cells to induce regression of established tumors leading to durable elimination of tumor burden
  • Elucidating the unique feature of g-NK cells which enable the development of an off-the-shelf cancer immunotherapy combined with therapeutic IgG antibodies
  • Combining g-NK cells with anti-CD38 antibodies for the treatment of multiple myeloma without the need for genetic engineering

10:30 am Low pH-Induced Polarization of Human Macrophages Toward a Pro- Tumorigenic, Wound repair Phenotype is Fully Reversed by Small Molecule Inhibitors of GPR65: Implications for Cancer Immunotherapy


  • The extracellular microenvironment of solid tumors is typically much more acidic than surrounding tissue
  • This acidic environment has a profound effect on macrophages and other innate immune cells, leading to a pronounced polarization of these cells toward a protumorigenic or wound repair phenotype
  • Pathios proprietary small molecule GPR65 inhibitors are able to fully counteract this polarization in vitro and bring about activation of the innate immune system in viv

11:00 am Morning Refreshment Break

11:30 am The CD47-SIRPα Myeloid Checkpoint in Cancer & its Therapeutic Targeting with BYON4228

12:00 pm Drug Development Journey for Macrophage-Directed Therapies Through QPCTL: a Novel Drug Target to Modify the CD47 Immune Checkpoint

12:30 pm Lunch Break

1:30 pm The Anti-Fibrotic Drug Nintedanib Promotes Resolution Phenotype Macrophages

  • Karim Kasmi Senior Principal Scientist , Boehringer Ingelheim

2:00 pm Igniting IFNg Responses to Overcome Resistance with a Novel Macrophage Checkpoint

  • Juho Jalkanen Chief Development Officer , Faron Pharmaceuticals


  • CLEVER-1 is a master immunosuppressive scavenger receptor on TAMs
  • Bexmarilimab, a first in class anti-CLEVER-1 mAb, is the first macrophage checkpoint
    to show single agent activity in advanced solid tumors
  • Bexmarilimab works by igniting IFNg responses where they do not exist, paving the
    road for classical checkpoint inhibitors

2:30 pm Closing Panel: The Future of Innate Immune Checkpoints & Activation


  • Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment
  • Discussing novel checkpoint inhibitors
  • Analysing the various immunotherapy approaches discussed & beyond
  • Updates on clinical trials for immunotherapies
  • In vitro models and discovery technologies for innate cell-based therapies
  • New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq, mass cytometry, highresolution IHC/ISH)